Green Lifescience KRX:114450KOSDAQ
그린생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Green Lifescience reported revenue of ₩19.0bn, up 65.8% year on year, and operating profit of ₩1.8bn. Green Lifescience (그린생명과학) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Screener
Green Lifescience quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩19.0bn | +65.8% | ₩1.8bn margin 9.5% | ₩4.4bn |
| Q1 2026 | ₩15.5bn | +219.2% | ₩585m margin 3.8% | ₩1.8bn |
| Q4 2025 derived | ₩12.6bn | +81.7% | ₩1.2bn margin 9.7% | ₩730m |
| Q3 2025 | ₩11.4bn | +155.1% | ₩105m margin 0.9% | ₩490m |
| Q2 2025 | ₩11.5bn | +66.0% | ₩58m margin 0.5% | ₩36m |
| Q1 2025 | ₩4.9bn | -25.5% | −₩1.1bn margin −23.3% | −₩1.1bn |
| Q4 2024 derived | ₩7.0bn | +88.9% | −₩432m margin −6.2% | ₩254m |
| Q3 2024 | ₩4.5bn | -40.4% | −₩627m margin −14.1% | −₩1.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Green Lifescience top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Green Lifescience news Korean headlines
No articles yet.